Pipeline

Programs centered on adipocyte-mediated energy expenditure

Energesis’ pipeline includes a repurposed drug combination, follow-on small molecule candidates, and earlier-stage biologics.

Program	Modality	Route	Furthest development	Completed
EGS-2632 Obesity · Proprietary oral combination of two previously approved drugs	Small molecule (repurposed combination)	Oral	Preclinical	Preclinical studies in diet-induced obesity mouse models demonstrating statistically and clinically significant body weight reduction, fat-selective weight loss, lean mass preservation, increased BAT-mediated energy expenditure, and synergistic efficacy with marketed GLP-1 agents.
Small Molecule NCEs Obesity · Novel small molecule compounds identified via proprietary human brown fat discovery platform	Small molecule (novel chemical entities)	Oral	Lead Optimization	Novel target identified, lead compound selected with convincing in vivo data set, currently optimizing lead of follow-on compounds.
Biologics Program Obesity / metabolic disease · Earlier-stage biologics targeting adipocyte-mediated energy expenditure	Biologic	Injectable	Target ID / Early Discovery	Earlier-stage program, target identified, convincing in vivo data set, developing improved compounds.

Lead program

EGS-2632: a proprietary oral combination candidate

EGS-2632 is Energesis’ lead product candidate. It is a proprietary oral combination of two previously approved drugs being developed for obesity.

In studies using the workhorse small animal model of obesity, the diet-induced obese mouse, EGS-2632 produced statistically and clinically significant body weight reduction. This weight loss comes entirely from fat, with complete preservation of lean mass.

Both components have established safety records at their approved doses. In EGS-2632 they are used together at only a fraction of those doses. Neither drug significantly affects body weight alone; however, together they act synergistically.

Preclinical data

What the animal studies show

Energesis’ preclinical efficacy and mechanism-of-action studies show that EGS-2632 increases energy expenditure through increased brown fat mass. (EGS-2632 combines EGS-2026 and EGS-2032). Select a chart to enlarge it.

Body weight: statistically and clinically significant weight loss after 32 days of oral dosing, with separation continuing through 52 days.

Quality of weight loss: all weight lost came from fat, while lean muscle mass was preserved.

Mechanism: food intake was not reduced; total brown fat thermogenic capacity was elevated.

With GLP-1s: synergistic efficacy with marketed GLP-1 drugs in a preclinical study.

Preclinical data note: Animal data may not translate to human efficacy or safety. Additional studies are required.

Combination potential

Potential complement to GLP-1 therapies

We do not view GLP-1 drugs as competitive. Because GLP-1s act on energy intake, an energy expenditure therapy could potentially be used as an adjunctive or sequential treatment strategy.

In preclinical studies, EGS-2632 showed synergistic efficacy when combined with marketed GLP-1 agents. We believe this may support future development as a combination approach, GLP-1 dose-sparing strategy, or weight maintenance option.

Combination Therapy

Potential use alongside GLP-1 therapies to improve total weight loss or support fat-selective outcomes.

GLP-1 Intolerant Patients

Potential use in patients who cannot tolerate or remain on incretin therapies.

Maintenance Therapy

Potential long-term oral strategy after initial weight loss to support weight maintenance and prevent weight regain.

Combination potential

Beyond appetite suppression

We believe the future of obesity care will require therapies that do more than suppress appetite. By targeting brown fat recruitment and energy expenditure, we are pursuing an approach intended to support fat-selective weight loss, preserve lean mass, and work alongside GLP-1 therapies.

Oral lead candidate strategy
Designed to increase energy expenditure without reducing food intake
Potential to preserve lean mass based on preclinical studies
Potential adjunctive use with GLP-1 therapies based on preclinical data
Small molecule approach with straightforward, easily scalable manufacturing potential

Regulatory pathway

Planned path toward human translation

We are developing our assets for obesity. We intend to perform a validation study of EGS-2632 in obese non-human primates.

Subsequently, we plan to perform a pilot human study ex-U.S., and then incorporate this safety data into an IND submission to the FDA. We expect to partly use the 505(b)(2) pathway, which may allow reliance on prior FDA safety findings for one component, published safety literature for the second component, and targeted original clinical studies for the combination.

Preclinical Stage

Where we are today

NHP Validation Study

Obese non-human primates

Ex-U.S. Human Study

Pilot safety and efficacy study

Future FDA IND

Potential 505(b)(2) pathway

Energesis’ programs, including EGS-2632, are currently in preclinical development. They have been evaluated only in laboratory and animal models and have not yet been tested in humans. They are not approved by any regulatory authority, and preclinical results may not predict human safety or efficacy.